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Abstract Mechanosensation (the ultimate conversion of a
mechanical stimulus into a biochemical signal) as well as
mechanotransduction (transmission of mechanically induced
signals) belong to the most fundamental processes in biology.
These effects, because of their dynamic nature, are particularly
important for the cardiovascular system. Therefore, it is not
surprising that defects in cardiac mechanosensation, are
associated with various types of cardiomyopathy and heart
failure. However, our current knowledge regarding the genetic
basis of impaired mechanosensation in the cardiovascular
system is beginning to shed light on this subject and is at the
centre of this brief review.









MARP Muscle ankyrin repeat protein
SL Sarcomere length
Introduction
Cardiovascular disease (CVD) is the largest source of
morbidity and mortality in the European Union; the
financial burden totals 169 billion Euros annually with
healthcare accounting for 62% of costs [1] and the WHO
expects CVD to become the leading cause of death
worldwide by 2015. In addition to the economic impact,
individuals affected by CVD experience a significantly
impaired quality of life as well as a reduced life expectancy
(i.e. 50% of all patients affected by severe heart failure die
within 5 years of diagnosis, which makes the mortality rate
for heart failure comparable to that of cancer).
Unfortunately, and in contrast to the socioeconomic
importance of CVD, our present knowledge regarding the
underlying disease causing molecular mechanisms of heart
failure, remains elusive as the foundation for novel
therapeutic approaches are limited.
Cardiomyopathies are primary diseases of the heart
muscle and major causes of heart failure associated with
high morbidity and mortality [2]. In particular, hypertrophic
cardiomyopathy (HCM; prevalence, 1/500) and dilated
cardiomyopathy (DCM; prevalence, 1/2,500) are very
common. Cardiomyopathies can also be due to a variety
of different infections (“myocarditis”), the consequence of
exposition to many different toxins or drugs, including
alcohol and some rare cases due to mutations in the
mitochondrial genome. However, an estimated 80% of all
HCM and probably at least 30% of all DCM cases are
hereditary, which points to the importance of genetic factors
[3, 4]. In the last 10–20 years, a variety of different
mutations in a wide range of different genes encoding
mainly cytoskeletal or sarcomeric components have been
identified as causative in several familial cardiomyopathies
(for a recent review please see [5]). The analysis of these
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genes, including the analysis of their mutations is not only
important for CVD per se, but this research offers the
unique possibility to use this “experiment of nature” to get
a deeper insight into gene function and cellular biology,
particularly because our knowledge of how single basepair
changes cause complex diseases is very limited.
As such, a variety of different mechanisms have been
proposed to explain how changes in the genetic composi-
tion are associated with cardiomyopathy and different
forms of heart failure. Among them are defects in force
generation and or force transmission, changes in calcium
sensitivity and metabolism, in mechanosensation as well as
in mechanotransduction. Cardiomyopathy and heart failure
due to imperfect mechanosensation is a relatively new
hypothesis to explain the pathogenesis of cardiac diseases.
In addition to this, defects in mechanosensation might be
difficult to prove in the experimental context because large-
scale assays to check for such defects are missing.
Here, we discuss briefly some of the most important
mechanisms involved in cardiac mechanosensation as well
as their implications for different types of cardiomypathy
and human heart failure. We focus primarily on cytoskeletal
and sarcomeric components rather than on ion channels,
which have been recently elegantly reviewed [6].
Life as we know it today is unimaginable without
mechanosensation—a highly conserved process found in a
wide variety of different cell types, tissues, organs and even
at the level of single-cell organisms [7]. Different environ-
mental conditions during evolution led to the development
of extremely divergent stretch sensing mechanisms in these
cell types. As a consequence, there is no common
“mechanosensation mechanism” present nor is there “one
single mechanosensation mechanism” responsible for all
mechanosensory effects observable in a single cell. This
is particularly true for cardiomyocytes where different
mechanisms are simultaneously involved to integrate a
multitude of mechanical stimuli into biochemical signals.
These stimuli include passive effects induced by blood flow
and shear stress as well as active effects caused by cycles of
contraction and relaxation of single cardiomyocytes. From
this point of view, it is also clear that cardiomyocytes are in
need of different types of mechanosensors such as length and
force sensors that are necessary to identify different mechan-
ical stimuli (Fig. 1).
Length (Strain) Sensor—Titin
Titin is the largest molecule known in biology, it may
add up to 4.2 mDa and has an in situ length of about 1–2μm in
the passive cardiac myocyte, spanning from the Z-disc to
the M-band of the sarcomere. Active force in the form of
stretch is related to the change in the length of
sarcomeres within the ventricular myocytes. When a
cardiac myocyte is stretched, there is an increase from
resting sarcomere length (SL) approximately 1.9 μm up
to a maximum at a length (Lmax) of =2.2–2.3 μm (please
see for an review on this topic the article by Granzier and
Labeit [8]). Beside the thin (actin) and thick filaments
(myosin), titin is called the “third” filament. As such, it is
no surprise that this molecule fulfils many different
functions, such as serving as a molecular ruler. Titin is
also an important factor during embryonic development
and influences via its interactions with myosin binding
protein C directly myocardial contractile function [9].
However, one of the most important functions of this
“titanic” molecule is to retain the cardiomyocyte in an
optimal length, which is achieved in the myocardium by
three different molecular springs: the PEVK (rich in
proline, glutamate, valine and lysine), the tandem immu-
noglobulin (Ig) as well as the N2B domains, which encode
cardiac specific-titin transcripts. All three domains are
localised in the I-band of the sarcomere perfectly suited to
sense any change in sarcomeric length (please see for a
review on titin elastic domains the article by Granzier and
Labeit [10])
The PEVK, tandem Ig and N2B domains interact with a
variety of different proteins, for example the N2-A domain
binds (next to a calpain protease, p94 or calpain-3 binding site)
a protein complex consisting of muscle ankyrin repeat proteins
(MARPs, including diabetes-associated ankyrin repeat pro-
teins (DARP), cardiac ankyrin repeat proteins (CARP) and
Ankrd-2), which in turn bind myopalladin. Upon stretch,
DARP and CARP translocate to the nucleus where they
probably participate in the orchestration of a stretch-dependent
gene programme [11]. This is supported by the fact that
Ankrd-1 and 2 bind transcription factors, such as PML, YB-1
or p53, and are able to potentiate the effects of p53 on the
p21 promoter [12, 13]. Interestingly, ablation of the PEVK
domain in a genetically altered mouse model leads to a defect
in passive elasticity, myocardial hypertrophy and diastolic
heart failure, together with FHL2 upregulation [14].
Another link between titin, length sensation and gene
expression is provided by the binding of N2B titin to four
and a half LIM domain protein 1 (FHL1), Raf, MEK1/2
and ERK2 which links titin directly to G protein-coupled
(GPCR) signalling and regulates cardiomyocyte length and
hypertrophic gene expression [15].
Over the last decade, a number of titin mutations
associated with various muscle pathologies such as DCM,
HCM or tibial muscular dystrophy have been reported but
the precise series of molecular events leading to the
phenotypes remain unclear (for an overview please see
[16]). It is impossible to discuss all of these genetic variants
here, however mutations particularly localised in the N2B
region such as the HCM-associated S3799T, which
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increases binding to FHL2 and the DCM-associated
Q4053ter mutation which decreases titin's affinity to
FHL2 do probably have effects on mechanosensation.
Another mutation, the S4465D-titin, is directly localised
in the FHL2 binding site [17, 18].
Another link to mechanosensation is probably provided
by mutations localised in ANKRD1 or CARP, where three
mutations have been reported recently in various patients
affected by DCM. In particular, the P105S and M184I
substitutions result in loss of binding with talin, a key
binding partner of the beta-integrin subunit of the integrin
complex and as such links CARP not only via titin but also
via talin potentially to mechanosensation. In addition, the
M184I variant results also in loss of CARP interaction with
FHL2 [19]. Interestingly, the same group identified three
additional CARP mutations (P52A, T123M, I280V), this
time associated with HCM leading to an increase of affinity
between CARP and titin [20].
Vice versa, the recently discovered G48S—FHL2
variant abolishes to a large extent the titin/FHL2
interaction and has been found in an individual affected
by DCM [21]. However, although the data provided do
strongly support the idea that human mutations affect titin-
mediated mechanosensation and lead to cardiomyopathy
and heart failure, it remains to be seen if more detailed and
additional binding studies in solution can confirm this
concept.
Moreover, the elastic properties of the N2-B domain of
titin are significantly influenced by phosphorylation which
can in principle affect the mechanosensitive function of this
segment—however, experimental prove for this hypothesis
is missing [16]. It can be hypothesised that mutations
affecting these phosphorylation sites may also affect titin's
ability to sense stress.
A completely different mechanism of length sensation
has been proposed for titin's kinase domain, located at the
M-band of the sarcomere. This domain has been found to
interact with signalling molecules such as Nbr1, p62 and
the E3 ubiquitin ligase, MURF2 [22]. Mechanical inactivity
is associated with nuclear translocation of MURF2 in
exchange for serum response factor (SRF) and transcrip-
tional repression. Interestingly, a titin kinase mutation
(R279W, located in the αR1 part of the regulatory tail) is
associated with hereditary myopathy with early respiratory
failure [22]. Titin kinase might be involved in short-term
mechanosensing, e.g. by phosphorylating a target protein
depending on the sarcomeric stretch state [23], but also in
long-term effects such as changing the hypertrophic gene
expression pattern. However, a titin kinase mutation linked
to human cardiomyopathy has not yet been reported.
Furthermore, in a recent report where MURF1 and MURF2
deficient animals were employed, it turned out that the
relationship between MURF2 and SRF is probably even
more complex [24]. Therefore it is necessary that future
studies are carried out, including the generation of
conditional knock-in models for this titin kinase mutation
followed by the detailed analysis of its distinct function in
cardiac mechanosensation.
The Sarcomeric Z-Disc
Z-discs define the lateral boundaries of sarcomeres, the
smallest functional units in cross-striated muscles. They
Fig. 1 The figure summarises
some of the postulated mecha-
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belong to the most complex macromolecular structures
in biology which are probably composed of hundreds
of different proteins [25]. Because of their anatomical
localization, they are nodal points for mechanosensation,
mechanotransduction, for mechanical stability and force
transmission as well as for embryonic development. They
probably do not function as length sensors like titin but
due to their exposition to stress particularly during
systole, they may serve as strain (tension, force) sensors.
As a consequence, almost all molecular components of
the sarcomeric Z-disc might be involved in mechanosen-
sation and mutations in their genes might give rise to
cardiomyopathy and heart failure via defects in this
system. In fact, the sarcomeric Z-disc is increasingly
recognised as a hot spot for cardiomyopathy and heart
failure causing mutations [26, 27].
One of the implicated genes in cardiomyopathy and
heart failure is the muscle LIM protein (MLP) or
cysteine rich protein 3. It is a 194 amino-acids protein
that is predominantly expressed in muscle tissues, with
an important role in myocardial function and perfor-
mance (for a brief overview please see: [28]). This
protein has been shown to be involved in cardiac
mechanosensation, possibly by functioning as a tension
sensor. MLP binds to telethonin (TCAP) which is known
to interact with titin's extreme N-terminal Z1/Z2 domains.
Upon an increase in biomechanical stress, MLP has been
shown to translocate to the nucleus using its nuclear
localization signal located within the first glycine rich
domain (GRD) [29]. Interestingly, mutations in MLP as
well as telethonin (TCAP) have been shown to be
associated with different forms of cardiomyopathy [30–
32]. Although MLP, telethonin and titin's N-terminal Z1/
Z2 domain were suggested to build a macromolecular—
mechanosensitive structure, the precise molecular mech-
anism by which this structure perceives mechanical
stimuli and transforms them into biochemical signals
remains unclear. Alternatively, Furukawa et al. have
speculated the interaction of telethonin with titin and
MinK, the β-subunit of potassium current (Iks) channel,
may contribute to a stretch-dependent regulation of potassium
flux in cardiac muscle, serving as a “mechano-electrical
feedback” system [33]. In this context, it is probably
important to mention our finding of an interaction between
MLP and integrin-linked kinase (ILK) as well as of
additional mutations localised in the ILK as well as laminin
alpha 4 genes, which are also associated with cardiomy-
opathy and heart failure [34, 35]. Although we did not
look for defects in mechanosensation when we performed
this set of experiments, defects in this system seem to be
likely because integrins are well known to be involved in
the perception and transmission of mechanical stimuli
(Table 1).
Intermediate Filaments
Intermediate filaments provide physical links between Z-
discs of peripheral sarcomeres and the sarcolemma at
costameres (and via these to the ECM). In addition to this,
also between Z-discs of adjacent sarcomeres, Z-discs and
nuclei and cell-to-cell contacts at the desmosomes. Desmin
is a major intermediate filament and mainly present in
extranuclear compartments, whereas lamin A/C is a nuclear
membrane constituent. Both contain elastic domains, hence
are able to react to changes in cell morphology, and respond
by interacting with a wide variety of different proteins [36].
Mutations in desmin cause muscular dystrophy as well as
cardiomyopathies associated with conduction blocks and
arrhythmias leading to sudden death as well as arrhythmo-
genic right ventricular cardiomyopathy [37, 38]. Several
mechanisms have been made accountable for the effects of
these mutations, one of which is certainly that absence of
desmin at the Z-disc impairs the generation and transmis-
sion of force through misalignment of sarcomere units [39].
Another mechanism may involve disruption of the physical
pathway between the sarcomere and the nuclear membrane
which is mainly provided by desmin and where mutations
might cause disruption of the translation of changes in
sarcomere length into changes in gene expression [40].
In addition, lamin A/C mutations are the most common
cause of dilated cardiomyopathy and more than 200 different
mutations are known in this gene, which are linked to more
than ten different types of disease [36], among them
cardiomyopathy, muscular dystrophy and lipodystrophy.
The underlying disease causing molecular mechanisms for
mutations located in this gene are less well understood, but
studies based on desmin and lamin A/C knockout animal
models [41] suggest mutations in these genes are linked to
defects in mechanosensation and mechanotransduction [36].
Recent reports demonstrated the involvement of nesprin,
another nuclear envelope protein, in the development of
cardiomyopathy and heart failure in lamin A/C-deficient
animals, which points to the importance of nuclear mem-
brane stability in the myocardium. Moreover, lamin A/C-
deficient animals have additional defects in the hypo-osmotic
Table 1 Human proteins directly implicated with defects in cardiac
mechanosensation
Protein Mutation Phenotype Reference
Telethonin (TCAP) R87Q DCM [30, 31]
Muscle LIM protein W4R DCM/HCM [31, 32]
FHL2 G48S DCM [21]
Titin Various DCM/HCM [17, 18]
ANKRD1 (CARP) Various DCM/HCM [19, 20]
The table lists some proteins directly involved in mechanosensation
together with mutations implicated in this effect.
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reaction, pointing to a possible defect in mechanosensation
and perhaps defects in mechano-transcriptional coupling
[42]. The same group found as well that carvedilol treatment
leads to significant improvement of the cardiac phenotype in
these animals—it might be possible that defects in mecha-
nosensation are targetable by this strategy [43].
Angiotensin 2
Angiotensin 2 is a well-known mediator of cardiomyocyte
hypertrophy. Stretch of cardiomyocytes is associated with the
local release of angiotensin 2, activating the angiotensin 2
receptor 1 (AT1), which mediates mechanosensory effects,
perhaps via activation of MAP kinase signalling [44].
Even more important is that the AT1 receptor, without
binding angiotensin 2, is directly activated by stretch [45, 46].
This surprising finding demonstrates a previously unappre-
ciated role of the AT1 receptor in mechanosensation and
brings this molecule directly into the context of stress
perception in single cells. It is conceptually novel that the
AT1 receptor, a member of G protein-coupled receptor, is a
mechanical force-transducing molecule and mediates me-
chanical stress-induced cellular responses. An increase in left
ventricular mass which was produced by abdominal aortic
constriction, without significant increase in plasma renin
activity, was completely prevented with an ACE inhibitor or
AngII type 1 (AT1) receptor antagonists without any change
in afterload. In support of this finding, Frank et al. have
reported that the AT1 receptor blocker irbesartan markedly
blunted stretch-mediated GDF15 and Hmox1 upregulation,
suggesting that the angiotensin receptor tranduces the
biomechanical induction of these genes [47]. Besides this,
AngII activates many protein kinases, such as ERKs, JNK,
p38MAP kinase and JAK/STAT, and also induces expression
of IEG such as c-fos and c-jun genes as well as increases
protein synthesis in cardiac myocytes.
In summary, these results strongly suggest that the local
renin–angiotensin system, but not the circulating one, is a
major mediator of pressure overload-induced cardiac
hypertrophy. Once mechanical stress is perceived and
converted into biochemical signals, the activated signal
transduction pathway or pathways leading to changes in
cardiac myocyte structure and metabolism seem to be
similar to those pathways known to be activated by various
humoral factors such as growth factors, hormones and
cytokines in many other cells.
Mechanosensation and Genetics—Outlook
In summary, the above described, novel length and tension-
dependent intra- or extra-sarcomeric mechanosensation
mechanisms may play a significant role in the regulation
of myocardial hypertrophy, atrophy and sarcopenia. More-
over, mutations in these systems may lead to cardiomyopathy,
heart failure and arrhythmogenesis. Studies related to physio-
logical stretch signalling have been carried out decades ago,
but these reports were the first to specifically identify human
mutations in some of these components and to link them to
disease [31, 32, 34].
Although MLP and telethonin as well as titin's kinase
domain have been directly or indirectly implicated in the
process of mechanosensation and human mutations have
been linked to types of heart and or muscle pathologies, at
present, most other mutations known to cause various
types of cardiac pathology have not been studied under
this aspect in such detail. One of the reasons as to why
they have not been examined in this context is due to the
complexity associated with the analysis of mechanosen-
sation, which is a multifaceted response to various
mechanical stimuli and as such requires the presence of
a living cell or at least functioning large macromolecular
protein compounds.
In addition, future research should be directed to
translate our knowledge of mechanosensation into novel
therapeutic strategies, possible targets might include FAK,
ILK (kinase inhibitors, activators) and or interventions at
the level of nuclear translocation of some of the mediators
of mechanosensation (such as MLP, MARP).
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